Workflow
北陆药业:碘海醇注射液获匈牙利批准上市

Core Viewpoint - Northland Pharmaceutical Co., Ltd. has received approval from the Hungarian drug regulatory authority for the marketing authorization of Iohexol injection, which enhances the company's international market competitiveness in contrast agents [1] Company Summary - The drug approved is Iohexol 350mg I/ml injection, with the registration number OGYI-T-24580/1 [1] - The approval date is June 11, 2025, and the validity period is five years [1] - This approval supports the company's efforts to expand into overseas markets and lays a solid foundation for sustainable development in the international market for contrast agents [1]